Foghorn Therapeutics Inc. cash flow to debt ratio of -208.62% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Foghorn Therapeutics Inc.'s free cash flow has increased -14.97% from $-101.31M last year to $-86.15M, signaling increasing performance

Foghorn Therapeutics Inc.'s debt to equity ratio is -0.55, signaling that the company spent its equity and risk bankruptcy.

Foghorn Therapeutics Inc.'s debt to equity ratio is -0.55, signaling that the company spent its equity and risk bankruptcy.

Foghorn Therapeutics Inc. has negative EBITDA, making leverage ratio unreliable

Foghorn Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Foghorn Therapeutics Inc.'s profit margin has increased (-30.36%) in the last year from -383.24% to -266.88%, signaling increasing performance

Foghorn Therapeutics Inc.'s short-term assets of $163.24M exceed its short-term liabilities of $59.74M

Foghorn Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Foghorn Therapeutics Inc.'s return on equity of 85.78%, is higher than 15.00%, indicating good performance

Foghorn Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Foghorn Therapeutics Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Foghorn Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Foghorn Therapeutics Inc. has negative free cash flow, indicating cash burn

Foghorn Therapeutics Inc.'s yearly earnings has increased -14.24% since last year from $-86.62M to $-74.28M, signaling increasing performance

Foghorn Therapeutics Inc.'s yearly revenue has increased 36.75% since last year from $22.60M to $30.91M, signaling increasing performance

ROIC -50.60% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Foghorn Therapeutics Inc.'s 3-year revenue CAGR of 17.14% is positive, indicating growing revenue over the past 3 years

Foghorn Therapeutics Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Foghorn Therapeutics Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Foghorn Therapeutics Inc. has insufficient data to evaluate this check.

Foghorn Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Foghorn Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Foghorn Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Foghorn Therapeutics Inc. is overvalued relative to its fair value price of -43.15 based on Earnings Fair Value model

Foghorn Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Foghorn Therapeutics Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Foghorn Therapeutics Inc. has a price-to-sales ratio of 13.25x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue